Efficacy of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a report of 40 cases
10.3760/cma.j.issn.0254-1785.2019.03.007
- VernacularTitle:Haplo-HSCT治疗重型再生障碍性贫血40例的疗效观察
- Author:
Hongfei WU
1
;
Xinsheng XIE
;
Dingming WAN
;
Rong GUO
;
Chong WANG
;
Ling SUN
;
Hui SUN
;
Zhongxing JIANG
;
Shaoying HOU
Author Information
1. 郑州大学第一附属医院血液科 450052
- Keywords:
Allogeneic hematopoietic stem cell transplantation;
Aplastic anemia;
Human leukocyte antigen
- From:
Chinese Journal of Organ Transplantation
2019;40(3):153-157
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and prognosis of haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for severe aplastic anemia (SAA).Methods The clinical data were retrospectively analyzed for 40 SAA cases undergoing haplo-HSCT from September 2013 to February 2018.The conditioning regimen contained cyclophosphamide,fludarabine and antithymocyte globulin with or without busulfan or low-dose total body irradiation.Cyclosporin A,short-term methotrexate and mycophenolate mofetil were dosed for preventing graft versus host disease (GVHD).The median counts of mononuclear cell and CD34+ stem cell were 5.3(2.0～13.5) × 108/kg and 5.6 (1.6 ～ 15.9) × 106/kg respectively.Results Among them,hematopoietic reconstitution was achieved (n =36,90.0 ％).The median times for myeloid engraftment and platelet engraftment were 15(10-25) and 17(10～58) days respectively.The incidence of acute graft-versushost disease(aGVHD)was (35.0± 6.8) ％.The incidence of chronic GVHD (cGVHD) was (23.0 ±7.4) ％.And 28 SAA cases (70.0 ％) survived during a median follow-up period of 353(30～1226)days,The cumulative overall survival (OS) was (67.8 ± 7.8) ％,the average survival time (883 ± 82)days and transplantation-related death (TRM) within 100 days (10.0 ± 3.1) ％.Conclusions Haplo-HSCT is an effective treatment for SAA patients.And a larger number of cases are required for enhancing OS.
